Skip to main content
Sinocare Inc. logo

Sinocare Inc. — Investor Relations & Filings

Ticker · 300298 ISIN · CNE100001CJ0 LEI · 3003008DEKI00A51LU77 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,250 across all filing types
Latest filing 2020-03-17 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300298

About Sinocare Inc.

https://www.sinocare.com

Sinocare Inc. specializes in the research, development, and manufacturing of biosensor technology and rapid testing products for chronic disease management. The company is primarily recognized for its blood glucose monitoring systems, including meters and test strips, which serve a global patient base. Its product portfolio extends to point-of-care testing (POCT) solutions for HbA1c, uric acid, blood lipids, and other metabolic indicators. Through the integration of advanced sensing technologies and digital health platforms, Sinocare provides comprehensive diagnostic tools for diabetes and related metabolic disorders. The company focuses on delivering affordable and accurate monitoring solutions to improve the quality of life for individuals with chronic conditions worldwide.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于公司变更募集资金投资项目的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed independent financial advisor's verification opinion regarding the change in the use of raised funds by a listed company, SanNuo Bio-sensing Co., Ltd. It references regulatory approvals, fundraising amounts, project investment details, and compliance with securities exchange rules. The document is issued by CITIC Securities as an independent financial advisor and includes extensive analysis of the fundraising projects, their completion, and the reallocation of surplus funds to a new R&D project. It is not a full annual or interim financial report, nor is it a simple announcement or certification. The content aligns with a Capital/Financing Update (CAP) as it deals with changes in the use of raised capital and investment projects funded by the raised capital. The document length and detail confirm it is not a brief announcement or a certification letter, but a substantive advisory report on fundraising capital usage changes.
2020-03-17 Chinese
关于筹划公开发行可转换公司债券的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (536 characters) regarding the company's plan to publicly issue convertible bonds. It mentions the board meeting approving the proposal and that the proposal has been disclosed on the regulatory website. There is no detailed financial data or full report included, only a notice about the planning and disclosure of a financing activity. This fits the definition of a Capital/Financing Update (CAP) rather than a full report or regulatory filing. The document is not a report publication announcement since it does not mention an attached report or provide a link to download a report, but rather it is an announcement of a financing plan.
2020-03-17 Chinese
关于公司变更部分募集资金投资项目的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company about changes in the use of previously raised funds from a non-public share issuance. It discusses the completion of an original investment project funded by raised capital, the surplus funds remaining, and the company's plan to reallocate these surplus funds to a new research and development project. The document includes detailed financial figures, project descriptions, approvals from the board, independent directors, and supervisory board, as well as regulatory compliance statements. It is not a full financial report like an Annual Report or Interim Report, nor is it a simple announcement of a report publication. The content focuses on capital management and changes in the use of raised funds, which aligns with the category of Capital/Financing Update (CAP). The document is lengthy and substantive, not a brief notice or certification, and it does not fit other categories such as M&A, legal proceedings, or governance information. Therefore, the best classification is Capital/Financing Update (CAP).
2020-03-17 Chinese
关于前次募集资金使用情况报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the usage of previously raised funds by the company 三诺生物传感股份有限公司. It includes specifics about the amount raised, the investment projects funded, the status of funds, and compliance with regulatory approvals from the China Securities Regulatory Commission. The document references the regulatory framework for fundraising and provides detailed financial figures related to the use and storage of the raised capital. It is not a general annual or quarterly report, nor is it an earnings release or management discussion. It is a comprehensive disclosure about the use of capital raised in a prior financing event, consistent with a Capital/Financing Update filing. The document length is substantial (9542 characters), and it contains actual financial data and project details, not just an announcement or certification. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-03-17 Chinese
关于公开发行可转换公司债券摊薄即期回报的风险提示与填补回报措施及相关主体承诺的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company regarding the public issuance of convertible bonds, specifically focusing on the dilution of immediate returns to shareholders, risk warnings, measures to compensate for dilution, and related commitments by the company and its directors. It includes financial assumptions, impact analysis on earnings per share, descriptions of the use of proceeds, and governance and operational measures to mitigate dilution effects. The document references regulatory guidelines from the China Securities Regulatory Commission and other government bodies, and it is structured as a formal public announcement rather than a full financial report or earnings release. It does not contain comprehensive financial statements or quarterly/annual financial results but rather focuses on capital raising and its impact on shareholders. Therefore, the document fits best into the category of Capital/Financing Update (CAP), as it provides detailed information about a financing activity (issuance of convertible bonds) and related shareholder impact and company measures.
2020-03-17 Chinese
独立董事关于第四届董事会第三次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various proposals related to the company's issuance of convertible bonds and related matters, prepared for submission to the company's 2020 first extraordinary general meeting of shareholders. It includes detailed legal and regulatory compliance statements, opinions on bond issuance plans, use of funds, shareholder return plans, and asset acquisitions. The document is not a financial report or earnings release but rather a formal opinion and recommendation document related to board and shareholder meeting agenda items. It is closely related to board/management information and meeting materials but is not a presentation or voting result announcement. Given the nature of the document as independent directors' opinions on board meeting matters, the best fitting category is Board/Management Information (MANG). The document length is 4589 characters, which is substantive and contains detailed opinions rather than a brief announcement or certification, so it is not RNS or RPA.
2020-03-17 Chinese

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.